115 related articles for article (PubMed ID: 28162291)
1. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism.
Vannini F; Kodela R; Chattopadhyay M; Kashfi K
Redox Biol; 2015 Aug; 5():421. PubMed ID: 28162291
[TBL] [Abstract][Full Text] [Related]
2. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
Vannini F; Chattopadhyay M; Kodela R; Rao PPN; Kashfi K
Redox Biol; 2015 Dec; 6():318-325. PubMed ID: 26319435
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.
Vannini F; MacKessack-Leitch AC; Eschbach EK; Chattopadhyay M; Kodela R; Kashfi K
Bioorg Med Chem Lett; 2015 Oct; 25(20):4677-82. PubMed ID: 26323873
[TBL] [Abstract][Full Text] [Related]
4. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Chattopadhyay M; Kodela R; Olson KR; Kashfi K
Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
[TBL] [Abstract][Full Text] [Related]
5. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.
Chattopadhyay M; Kodela R; Santiago G; Le TTC; Nath N; Kashfi K
Biochem Pharmacol; 2020 Jun; 176():113857. PubMed ID: 32061771
[TBL] [Abstract][Full Text] [Related]
6. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.
Kashfi K; Borgo S; Williams JL; Chen J; Gao J; Glekas A; Benedini F; Del Soldato P; Rigas B
J Pharmacol Exp Ther; 2005 Mar; 312(3):978-88. PubMed ID: 15528453
[TBL] [Abstract][Full Text] [Related]
7. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents.
Kashfi K
Redox Biol; 2015 Aug; 5():420. PubMed ID: 28162289
[TBL] [Abstract][Full Text] [Related]
8. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders.
Lee M; McGeer E; Kodela R; Kashfi K; McGeer PL
Glia; 2013 Oct; 61(10):1724-34. PubMed ID: 23918470
[TBL] [Abstract][Full Text] [Related]
9. Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling.
Nath N; Vassell R; Chattopadhyay M; Kogan M; Kashfi K
Biochem Pharmacol; 2009 Nov; 78(10):1298-304. PubMed ID: 19576865
[TBL] [Abstract][Full Text] [Related]
10. The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin.
Hua A; Mackenzie GG; Rigas B
Int J Oncol; 2009 Oct; 35(4):837-44. PubMed ID: 19724920
[TBL] [Abstract][Full Text] [Related]
11. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
Kodela R; Chattopadhyay M; Goswami S; Gan ZY; Rao PP; Nia KV; Velázquez-Martínez CA; Kashfi K
J Pharmacol Exp Ther; 2013 Apr; 345(1):85-94. PubMed ID: 23349335
[TBL] [Abstract][Full Text] [Related]
12. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.
Kodela R; Chattopadhyay M; Velázquez-Martínez CA; Kashfi K
Biochem Pharmacol; 2015 Dec; 98(4):564-72. PubMed ID: 26394025
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention.
Williams JL; Nath N; Chen J; Hundley TR; Gao J; Kopelovich L; Kashfi K; Rigas B
Cancer Res; 2003 Nov; 63(22):7613-8. PubMed ID: 14633677
[TBL] [Abstract][Full Text] [Related]
14. Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect.
Zhao W; Mackenzie GG; Murray OT; Zhang Z; Rigas B
Carcinogenesis; 2009 Mar; 30(3):512-9. PubMed ID: 19136474
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association.
Nath N; Kashfi K; Chen J; Rigas B
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12584-9. PubMed ID: 14566053
[TBL] [Abstract][Full Text] [Related]
16. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression.
Nath N; Labaze G; Rigas B; Kashfi K
Biochem Biophys Res Commun; 2005 Jan; 326(1):93-9. PubMed ID: 15567157
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism.
Gao J; Kashfi K; Rigas B
J Pharmacol Exp Ther; 2005 Mar; 312(3):989-97. PubMed ID: 15528452
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Potential of Nitric Oxide and Hydrogen Sulfide (NOSH)-Releasing Synthetic Compounds as Novel Priming Agents against Drought Stress in
Antoniou C; Xenofontos R; Chatzimichail G; Christou A; Kashfi K; Fotopoulos V
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936819
[TBL] [Abstract][Full Text] [Related]
19. NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes.
Ricciotti E; Dovizio M; Di Francesco L; Anzellotti P; Salvatore T; Di Francesco A; Sciulli MG; Pistritto G; Monopoli A; Patrignani P
J Immunol; 2010 Feb; 184(4):2140-7. PubMed ID: 20065114
[TBL] [Abstract][Full Text] [Related]
20. NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines.
Tesei A; Ricotti L; Ulivi P; Medri L; Amadori D; Zoli W
Int J Oncol; 2003 Jun; 22(6):1297-302. PubMed ID: 12738997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
